Quarterly Report I 15/16
September 2015 – November 2015Diamyd Medical AB (publ), Fiscal year 2015/2016Reporting period, September 1, 2015 – November 30, 2015 · Net result amounted to MSEK -4.3 (-5.9) · Net result per share amounted to SEK -0.2 (-0.3) · Cash flow from operating activities amounted to MSEK -4.8 (-5.8) · Liquid assets and short term investments amounted at the end of the period to MSEK 24.9 (29.8) Significant events after the reporting period · Preliminary 15-month results from DIABGAD, a 30-month pilot study with the diabetes vaccine Diamyd® in combination with vitamin D and